MiRNA-221/222 in thyroid cancer: A meta-analysis

Abstract Objectives A meta-analysis was performed to observe whether a difference in miRNA-221/222 expression exists in thyroid cancer with normal thyroid or BTLs (benign thyroid lesions) and, under this premise, assess its diagnostic efficacy for thyroid cancer. Methods Systematic electronic literature searches were conducted to include PubMed, the Cochrane Central Register of Controlled Trials, and Web of Science. The combined fold change (FC) was calculated, and pooled estimates of sensitivity, specificity, diagnostic odds ratio (DOR) and summary receiver operating characteristic (SROC) curves were calculated. Results Twenty-seven articles were included in this meta-analysis. The combined FC of miRNA-221/222 were 13.85 and 13.75 in thyroid cancer with normal control. For miRNA-221/222, the pooled sensitivity was 0.79 (95% CI = 0.73–0.85), specificity was 0.84 (95% CI = 0.76–0.90) and AUC (area under the curve) value was 0.88 (0.85–0.91). For miRNA-221, the pooled sensitivity was 0.82 (95% CI = 0.76–0.86) and specificity was 0.84 (95%CI = 0.74–0.91). For miRNA-222, the pooled sensitivity was 0.78 (95%CI = 0.68–0.85) and specificity was 0.83 (95% CI = 0.70–0.92). Conclusion Differences in expression levels of miRNA-221/222 can provide clues for exploring the etiology of thyroid cancer. In addition, miRNA-221/222 were promising molecular biomarkers that may significantly improve the diagnostic accuracy of thyroid cancer.